Hims & Hers Health is still a Strong Buy, given that the transformative partnership with Novo Nordisk resolves legal risks and unlocks new growth avenues. HIMS' core value lies in its 2.5M+ cash-pay ...

Barclays expects accelerating revenue and EBITDA growth in the second half of 2026, supported by weight-loss offerings.

Hims & Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors pile into the stock ahead of a May 11 earnings report. The move caps a ...

Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage with an Overweight rating and a $35 price target, framing the telehealth ...

Hims had 2.6 million subscribers in Q1, up 9% year over year, with Q2 expected to show how much the Novo deal is helping demand.

Hims & Hers Health shares popped Monday after the telehealth company announced a new partnership with Novo Nordisk. The deal will allow Hims & Hers to sell the Danish drugmaker's weight-loss products ...

Novo Nordisk said on Monday it will sell its blockbuster Wegovy and Ozempic drugs through the U.S. telehealth company Hims & Hers Health platform, ending a legal dispute that erupted last month. The ...

Hims & Hers shares opened more than 40% on Monday after the company ended a dispute with Novo Nordisk and struck another partnership with the Danish drug giant. The company’s stock HIMS hovered around ...

March 9 (Reuters) - Hims & Hers' shares were up ⁠over ⁠40% on Monday, after ⁠Novo Nordisk agreed to sell its blockbuster Wegovy and Ozempic drugs through the telehealth firm's platform, signaling an ...

March 9 (UPI) --Shares of Hims & Hers jumped as much as 55% Monday after Novo Nordisk announced it is dropping its lawsuit over Ozempic and Wegovy copycat drugs. Novo Nordisk and Hims & Hers reached ...